Review article: Faecal occult blood testing for colorectal cancer

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 1, 1998, Pages 1-10

  Allison, J E ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CANCER SCREENING; COLORECTAL CANCER; COST BENEFIT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; OCCULT BLOOD; PRIORITY JOURNAL; REVIEW;

COLONIC POLYPS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; GUAIAC; HUMANS; INDICATORS AND REAGENTS; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SIGMOIDOSCOPY; UNITED STATES;

EID: 0031984357     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00231.x     Document Type: Review

References (52)

1. Woolf SH. Screening for colorectal cancer. In: US Preventive Services Task Force. Guide to Clinical Preventive Services. Baltimore: Williams & Wilkins, 1996: 89-103.
2. Fleisher M, Winawer SJ, Zauber AG, Smith C, Schwartz MK. Accuracy of fecal occult blood test interpretation. National Polyp Study Work Group. Ann Intern Med 1991; 114: 875-6.
3. Niv Y. Fecal occult blood test: the importance of proper evaluation. J Clin Gastroenterol 1990; 12: 393-5.
4. Simon JB. Occult blood screening for colorectal carcinoma: a critical review. Gastroenterology 1985; 88: 820-37.
5. Van Dam J, Bond JH, Sivak MV Jr. Fecal occult blood screening for colorectal cancer. Arch Intern Med 1995; 155: 2389-402.
6. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365-71. [Published erratum appears in N Engl J Med 1993; 329(9): 672.]
7. Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-7.
8. McGarrity TJ, Long PA, Peiffer LP, Converse JO, Kreig AF. Results of a television-advertised public screening program for colorectal cancer. Arch Intern Med 1989; 149: 140-4.
9. McGarrity TJ, Long PA, Peiffer LP. Results of a repeat television-advertised mass screening program for colorectal cancer using fecal occult blood tests. Am J Gastroenterol 1990; 85: 266-70.
10. Winchester DP, Shull JH, Scanlon EF, et al. A mass screening program for colorectal cancer using chemical testing for occult blood in the stool. Cancer 1980; 45: 2955-8.
11. Allison JE, Feldman R, Tekawa IS. Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value: long-term follow-up in a large group practice setting. Ann Intern Med 1990; 112: 328-33.
12. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-71.
13. Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracy of fecal occult blood screening for colorectal neoplasia. J Am Med Assoc 1993; 269: 1262-7.
14. Jahn H, Joergensen OD, Kronborg O, Fenger C. Can Hemoccult II replace colonoscopy in surveillance after radical surgery for colorectal cancer and after polypectomy? Dis Colon Rectum 1992; 35: 253-6.
15. Bang KM, Tillett S, Hoar SK, Blair A, McDougall V. Sensitivity of fecal Hemoccult testing and flexible sigmoidoscopy for colorectal cancer screening. J Occup Med 1986; 28: 709-13.
16. St. John DJB, Young GP, Alexeyeff MA, et al. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 1993; 104: 1661-8.
17. Norfleet RG. Effect of diet on fecal occult blood testing in patients with colorectal polyps. Dig Dis Sci 1986; 31: 498-501.
18. Macrae FA, St. John DJB. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 1982; 81: 891-8.
19. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996; 334: 155-9.
20. Mandel JS, Bond JH, Bradley M, et al. Sensitivity, specificity, and positive predictivity of the Hemoccult test in screening for colorectal cancers. The University of Minnesota's Colon Cancer Control Study. Gastroenterology 1989; 97: 597-600.
21. Winawer ST, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642.
22. Frommer DJ. Hemoccult test and colorectal cancer [letter]. Gastroenterology 1990; 99: 607-8.
23. Ferrante JM. Colorectal cancer screening. Med CHn North Am 1996; 80: 27-43.
24. Young GP, St. John DJB. Screening for colorectal cancer: the accuracy of fecal occult blood [letter]. J Am Med Assoc 1993; 270: 451-3.
25. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980; 64: 1263-72.
26. Uno Y, Munakata A. Endoscopic and histologic correlates of colorectal polyp bleeding. Gastrointest Endosc 1995; 41: 460-7.
27. Young GP, St. John DJB. Fecal occult blood tests: choice, usage and clinical applications. Clin Biochem Rev 1992; 13: 161-7.
28. Foutch PG, Haynes WC, Sanowski RA, Bellapravalu S, Kelly S. Incidence of colonic polyp bleeding (PRB): correlation with polyp size, histology and appearance. Gastroenterology 1985; 88: 1386 (Abstract).
29. Ransohoff DF, Lang CA. Small adenomas detected during fecal occult blood test screening for colorectal cancer: the impact of serendipity. J Am Med Assoc 1990; 264: 76-8.
30. Applegate WB, Spector MH. Colorectal cancer screening. J Community Health 1981; 7: 138-51.
31. Wagner JL, Tunis S, Brown M, Ching A, Almeida R. The cost effectiveness of colorectal cancer screening in average-risk adults. In: Young G, Levin B, eds. Prevention and Early Detection of Colorectal Cancer. London: Saunders, 1996: 321-56.
32. Wagner JL, Herdman RC, Wadhwa S. Cost effectiveness of colorectal cancer screening in the elderly. Ann Intern Med 1991; 115: 807-17.
33. Brown ML. Screening for colorectal cancer [letter]. N Engl J Med 1993; 329: 1352-3.
34. Lieberman DA. Cost-effectiveness model for colon cancer screening. Gastroenterology 1995; 109: 1781-90.
35. Lang CA, Ransohoff DF. Fecal occult blood screening for colorectal cancer: is mortality reduced by chance selection for screening colonoscopy? J Am Med Assoc 1994; 271: 1011-13.
36. Levin B, Hess K, Johnson C. Screening for colorectal cancer: a comparison of three fecal occult blood tests. Arch Intern Med 1997; 157: 970-6.
37. Schwartz S, Dahl J, Ellefson M, Ahlquist DA. The 'HemoQuant' test: a specific and quantitative assay of heme (hemoglobin) in feces and other materials. Clin Chem 1983; 29: 2061-7.
38. Ahlquist DA, McGill DB, Schwartz S, Taylor WF, Ellefson M, Owen RA. HemoQuant, a new quantitative assay for fecal hemoglobin: comparison with Hemoccult. Ann Intern Med 1984; 101: 297-302.
39. Ahlquist DA, McGill DF, Fleming JL, et al. Patterns of occult bleeding in asymptomatic colorectal cancer. Cancer 1989; 63: 1826-30.
40. Ahlquist DA, McGill DB, Schwartz S, Taylor WF, Owen RA. Fecal blood levels in health and disease: a study using HemoQuant. N Engl J Med 1985; 312: 1422-8.
41. Ahlquist DA, Wieand HS, Moertel CG, et al. Accuracy of fecal occult blood screening for colorectal neoplasia: a prospective study using Hemoccult and HemoQuant tests. J Am Med Assoc 1993; 269: 1262-7.
42. Lance P. Fecal occult blood test: what's new? [Editorial] Gastroenterology 1993; 104: 1852-5.
43. Rozen P, Knaani J, Papo N. Evaluation and comparison of an immunochemical and a guaiac faecal occult blood screening test for colorectal neoplasia. Eur J Cancer Prev 1995; 4: 475-81.
44. Petrelli N, Michalek AM, Freedman A, Baroni M, Mink I, Rodriguez-Bigas M. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program. Surg Oncol 1994; 3: 27-36.
45. Feinberg EF, Steinberg WM, Banks BL, Henry JP. How long to abstain from eating red meat before fecal occult blood tests. Ann Intern Med 1990; 113: 403-4.
46. Robinson MHE, Marks CG, Farrands PA, Thomas WM, Hardcastle JD. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg 1994; 81: 448-51.
47. Shimbo T, Glick HA, Eisenberg JM. Cost-effectiveness analysis of strategies for colorectal cancer screening in Japan. Int J Technol Assess Health Care 1994; 10: 359-75.
48. Ransohoff DF, Lang CA. Improving the fecal occult-blood test. [Editorial] N Engl J Med 1996; 334: 189-90.
49. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256: 102-5.
50. Smith-Ravin J, England J, Talbot IC, Bodmer W. Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. Gut 1995; 36: 81-6.
51. Fletcher RH. Commentary. ACP Journal Club 1996 May-Jun; 124(3): 74.
52. Levin B. Screening for colorectal cancer. Cancer Control J 1996; 3: 1-8.